Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Gastric Cancer
Interventions
DRUG

Cetuximab Plus P-HDFL

Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.

Trial Locations (1)

100

Department of Oncology, National Taiwan University Hospital, Taipei

All Listed Sponsors
collaborator

Taipei Veterans General Hospital, Taiwan

OTHER_GOV

collaborator

National Health Research Institutes, Taiwan

OTHER

collaborator

Chang Gung Memorial Hospital

OTHER

collaborator

Tri-Service General Hospital

OTHER

lead

National Taiwan University Hospital

OTHER

NCT00275951 - Cetuximab Plus P-HDFL for the First-line Treatment of Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter